Data for: A pragmatic trial of glucocorticoids for community acquired pneumonia

This dataset was generated from a pragmatic, randomized controlled trial evaluating the effectiveness and safety of adjunctive low-dose glucocorticoids in adults hospitalized with community-acquired pneumonia (CAP) in Kenya. The study was conducted across 18 public hospitals between April 2022 and June 2024 to determine whether oral glucocorticoids, when added to standard care, reduce 30-day mortality compared with standard care alone in low-resource settings. A total of 2,180 participants were enrolled and randomized to receive either standard care (n = 1,091) or standard care plus glucocorticoids (n = 1,089). Data include baseline clinical and demographic characteristics, type and duration of glucocorticoid therapy, comorbidities, antibiotic use, vital status at multiple time points (14, 21, and 30 days), and records of adverse and serious adverse events for the 2180 participants. Follow-up completeness at day 30 was 95.5%.